The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ALMS | +319.21% | N/A | N/A | +108% |
| S&P | +15% | +87.87% | +13.44% | +28% |
Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.
Biotech innovator Alumis, focused on autoimmune therapies, reported a significant insider buy amid a year of robust stock gains.
Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh capital.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.07M | 0.0% |
| Gross Profit | $1.15M | 241.3% |
| Gross Margin | 55.66% | 0.0% |
| Market Cap | $415.22M | -17.7% |
| Market Cap / Employee | $2.26M | 0.0% |
| Employees | 184 | 68.8% |
| Net Income | -$110,752.00K | -18.9% |
| EBITDA | -$114,476.00K | -17.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $65.26M | -69.4% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $33.39M | 12.7% |
| Short Term Debt | $4.41M | 200.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -54.44% | 0.0% |
| Return On Invested Capital | -152.19% | 25.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$110,909.00K | -31.2% |
| Operating Free Cash Flow | -$110,909.00K | -32.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.23 | 1.28 | 0.97 | 0.86 | -164.59% |
| Price to Sales | 19.17 | 11.46 | 18.78 | - | |
| Price to Tangible Book Value | 1.23 | 1.28 | 0.97 | 0.96 | -172.17% |
| Enterprise Value to EBITDA | -1.74 | -1.68 | 1.64 | -0.66 | -74.30% |
| Return on Equity | -198.7% | -247.0% | -66.4% | -66.9% | - |
| Total Debt | $30.72M | $31.88M | $38.78M | $37.80M | 21.54% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
